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Abstract
Background: Community- or population-based longitudinal studies of cognitive ability with 
a brain donation end point offer an opportunity to examine relationships between pathology 
and cognitive state prior to death. Discriminating the earliest signs of dementing disorders, 
such as Alzheimer disease (AD), is necessary to undertake early interventions and 
treatments.
Methods: The neuropathological profile of brains donated from The University of Manchester 
Longitudinal Study of Cognition in Normal Healthy Old Age, including CERAD (Consortium to 
Establish a Registry for Alzheimer’s Disease) and Braak stage, was assessed by 
immunohisto-chemistry. Cognitive test scores collected 20 years prior to death were 
correlated with the extent of AD pathology present at death.
Results: Baseline scores from the Memory Circle test had the ability to distinguish 
between individuals who developed substantial AD pathol-ogy and those with no, or low, 
AD pathology. Predicted test scores at the age of 65 years also discriminated between 
these pathology groups. The addition of APOE genotype further im-proved the 
discriminatory ability of the model.
Conclusions: The results raise the possibility of identifying individuals at future risk of the 
neuropathological changes associated with AD over 20 years before death using a simple 
cognitive test. This work may facilitate early inter-ventions, therapeutics and treatments 
for AD by identifying at-risk and minimally affected (in pathological terms) individuals. 
Neil Pendleton and David M.A. Mann contributed equally to the study.
Introduction
Currently available drugs used to treat Alzheimer disease (AD) have only limited 
efficacy in ameliorating its symptoms once disease has been diagnosed. Current 
research focuses on the pathogenesis of AD in an attempt to develop drugs ideally able 
to prevent the progression of the pathological process before clinical symptoms 
develop, or at least able to slow progression once the disease is apparent [1]. Such 
an approach involving pre-symptomatic diagnosis requires a test which is able to 
diagnose the disease before it is clinically apparent or to identify a person’s risk of 
developing clinical AD at some later time. Ideally, the test should be related to the 
presence of the characteristic pathology of the disease. As such, a test could range from 
question-based tools to biomarkers or brain imaging. Important character-istics of such a 
test include simplicity, availability, financial cost and tolerability to the subject.
The prediction of clinical symptoms of AD has employed imaging methods [2] to 
detect early structural changes and has identified changes in levels of tau and amyloid-
beta (Aβ) in cerebrospinal fluid [3] and lipidomic profile in blood [4, 5] with only limited 
success. Cognitive testing offers an alternative, non-invasive, possibility for the 
prediction of AD: it can be performed easily and safely in a community setting, usually 
with little or no need for specialist equipment or particular technical skills.
Previous studies have reported associations between clinical dementia and 
performance scores from a variety of cognitive tests. Measures of executive function, 
assessed over a 4-year period, predicted the conversion of mild cognitive impairment 
(MCI) to dementia [6], and scores from tests of episodic, working and semantic 
memory predicted a similar conversion over a 5-year period [7]. Longer-term studies 
have shown that changes in scores examining global cognitive function, as measured by 
the Mini-Mental State Examination (MMSE), visuo-spatial memory and verbal fluency 
can predict clinical AD 9 years before diagnosis [8], and decreased scores of semantic 
memory and conceptual formation are predictive of dementia 12 years before symptoms 
[9]. Most recently, Rajan et al. [10] reported that a low composite test score incorporating 
episodic memory, executive function and global cognition was asso-ciated with the 
development of clinical AD over an 18-year follow-up period: individual test scores of 
these cognitive domains were also predictive of AD over the same follow-up period.
A major drawback in the interpretation of clinical studies relates to the lack of neuro-
pathological confirmation of AD. There are correlations between cognitive status and 
neocor-tical Aβ plaques [11] with densities of neuritic Aβ plaques correlating better 
than those of diffuse Aβ plaques [12, 13]. Similarly, there are correlations between 
neocortical neurofi-brillary tangles density and MMSE scores, Blessed scores and the 
score of global cognitive status [14, 15]. Associations between specific 
neuropsychological testing scores and AD pathology are less common. Scores in tests 
assessing episodic memory have been shown to associate with National Institute on 
Aging-Reagan Institute pathological criteria [16], and scores on the Wechsler Adult 
Intelligence Score information test, verbal fluency and recog-nition memory correlate with 
Braak stage [17], as do cumulative scores describing executive function, verbal memory, 
visuospatial construction and language [18]. However, in all these studies, the period 
between (the last) cognitive testing and post-mortem brain examination was short, usually 
only between 1 and 5 years. In addition, selection bias remains an issue regarding the 
recruitment of subjects into such studies.
In the present study, we investigated associations between 2 neuropathological 
diag-nostic indices of AD (CERAD [Consortium to Establish a Registry for Alzheimer’s 
Disease] and Braak stage) and a battery of neuropsychological test scores collected 
many years prior to death. Because the interpretation of test scores is dependent on a 
person’s age, and because the age points at which neuropsychological testing was 
done varied in this study, we fitted statistical models to individual clinical trajectories 
and used these to predict an individual’s test score at age 65 years for each 
participant. Associations between neuropathology, baseline test scores and estimated 
test scores at age 65 years were then examined.
Early stages of AD are characterised clinically by changes in short-term memory 
(hippo-campal function) as shown by psychological testing, and in spatial awareness, 
as shown by PET/SPECT imaging of parietal lobe hypometabolism, suggesting that a 
failure in temporo-parietal pathways might reflect the onset of the disease process [19]. 
Because of its ability to draw upon elements of temporoparietal function, we predict that 
the Memory Circle (MC) test employed in the present study may index early failures 
in the temporoparietal pathway, indicative of the beginnings of the AD 
pathological process. Data obtained in parallel from the use of other 
neuropsychological tests were employed as “comparators” in order to determine how 
well the MC test might perform relative to the other tests. 
Materials and Methods
Participants and Study Design
Subjects were participants in The University of Manchester Longitudinal Study of Cognition in 
Normal Healthy Old Age. People with evidence of dementia at the time of recruitment were ineligible 
for the study. The study began in 1983 and recruited a total of 6,542 healthy individuals, aged between 
42 and 92 years, in successive waves between 1983 and 1994. Participants had demographic, 
lifestyle and health information collected through study-specific self-report questionnaires and 
undertook biennial alternating batches of cognitive tests (test battery A and B) designed to assess 
various aspects of cognition including memory, processing speed, fluid intelligence and crystallised 
intelligence [20]. The MC test from test battery B, which assesses visuospatial episodic memory using 
an immediate free-recall paradigm, is of particular importance for the present study. Participants were 
presented with a circle comprising 12 sectors, each containing a line drawing of an easily recognised 
object, for 30 s. They were then presented with a circle showing the sectors and they had to recall the 
names of the objects into the correct sectors (Fig. 1). A score out of 12 was calcu-lated using the 
number of correctly remembered items in the correct location in the circle. Details of educa-tional level 
were collected using a self-report questionnaire and then standardised using the International 
Standard Classification of Education (ISCED) guidelines [21].
Between June 2004 and April 2006, surviving participants underwent assessment by the 
Telephone Instrument for Cognitive Status (TICS), a test of general cognitive function which allows 
a definition of cognitive impairment. We used 27 items from this test to assign a TICS27 score [22]. 
Using thresholds defined in this report, we classified participants as follows: 0–6 = dementia; 7–11 
= cognitive impairment not dementia; and 12–27 = normal cognition. Cognitive status at death was 
ascertained using a combination of last TICS27 score and patient notes obtained via the participants’ 
general practitioner.
Eighty-nine brains from the surviving 312 members (in 2003) of the total cohort were accessioned 
into the study. Following pathological examination, a subset of 75 brains exhibiting AD pathology 
(without any other co-pathologies) or pathologically normal for age was used for this study. Fourteen 
individuals had been excluded because of other neuropathological changes (dementia with Lewy 
bodies [n = 8], corticobasal degeneration [n = 2], argyrophilic grain disease [n = 2], Parkinson disease 
[n = 1] and aging-related tau astro-gliopathy [n = 1]). Three of the 75 individuals eventually included in 
this study did not have an MC measure for initial testing.
Fig. 1. Memory Circle test. Participants were presented with a circle comprising 12 sectors, each 
containing a line drawing of an easily recognised object, for 30 s. They were then presented with a 
blank circle showing the sectors and they had to recall the names of the objects into the correct 
sectors. 
Pathological Methods
One fresh hemi-brain was fixed in 10% neutral formalin for 3–4 weeks with the other hemi-brain frozen 
at –80  ° C. Standard blocks of frontal, cingulate, temporal (with hippocampus), parietal and occipital cortex, 
amygdala, corpus striatum, thalamus, midbrain, brainstem and cerebellum were cut from the 
fixed tissue and processed into wax blocks. Paraffin sections (6 µm) were immunostained for Aβ 
(Cambridge Bioscience, clone 4G8, 1: 3,000) and tau proteins phosphorylated at Ser202 and Thr205 
(P-tau) (Source Bioscience, clone AT8, 1: 750). For antigen retrieval, sections were microwaved in 0.1 M 
citrate buffer, pH 6.0 (P-tau) or immersed in 70% formic acid for 20 min (Aβ) prior to incubation with primary 
antibody.
The severity of neuritic plaques in the frontal, temporal and parietal cortex and in the hippocampus was 
used to assign the CERAD score [23], and the topographical distribution of P-tau pathology was used to 
assign the Braak stage [24]. 
DNA was extracted from frozen brain tissue using REDExtract-N-AmpTM Tissue PCR Kit (Sigma) or 
from blood (3 cases). The APOE genotype was determined using routine polymerase chain reaction 
methods [25]. APOE could not be determined for 9 participants because of lack of blood or frozen brain 
tissue, one of whom also lacked the baseline MC score. 
Statistical Analysis
The analysis relates the CERAD score (0–A vs. B–C) and the Braak stage (0–II vs. III–VI) to cognitive 
test scores at baseline and predicted scores at age 65 years. For demographics, t tests assessed 
differences in mean values at the first test occasion between the CERAD/Braak groups; the χ2 test was 
used for nominal variables. The Mann-Whitney test assessed differences in cognitive test scores 
between pathology groups. A p value of < 0.05 was considered significant. Scores from only 1 cognitive 
test (MC test) differed significantly between pathology groups; this was subsequently investigated to 
ascertain relationships between CERAD and Braak stage groups and MC score in regression analyses 
which also included sex, education level and APOE genotype. Results of these analyses are presented 
as odds ratios (OR) with 95% confidence intervals (CI) for membership of the CERAD (B–C) or Braak 
stage (III–VI) groups. Correlations between CERAD score (0, A, B and C), Braak stage (0–VI) and both 
baseline and predicted MC scores at age 65 years were assessed using the Spearman rank correlation 
coefficient.
To predict scores at age 65 years for all participants, “random effects” regression models, with 
age at test as a predictor together with sex, education level and APOE genotype and a “learning 
effect,” were fitted to repeated test scores. Previous exposure to a cognitive task may affect future 
performance, giving the advantage of higher test scores than would be expected. This can bias 
estimates of cognitive performance in longitudinal studies with repeated test use, attenuating the 
expected effect of increasing chronological age. This can be termed a practice or learning effect [26, 
27]. These models initially allowed both individual differ-ences in level (random intercept) and 
differences in change (random slope) in test scores with age but reverted to the simpler random 
intercept models when there was no significant evidence of differences in change over time. The 
possibility of a non-linear change with age was allowed for by including a quadratic age term in the 
models. To allow for a learning effect, a binary variable which distinguished between the first test and all 
later tests was also considered in the model. These models were then used to predict the scores at 
age 65 years for all participants. 
Data were analysed using the statistical software package SPSS (version 20) and the xtmixed 
software in STATA version 14. 
Results
Demographics
Demographic and descriptive characteristics of the 75 participants are shown in Table 1. 
There were no significant differences in sex, age at death, level of education or age at 
initial testing of test battery B (which included the MC test) between either CERAD score 
groups or Braak stage groups. As expected, a significantly greater proportion of 
individuals cognitively impaired at death were present in the high-severity pathology 
group (CERAD 56%; Braak 57%) than in the low-severity pathology group (CERAD 
21%; Braak 23%) for both CERAD  (p = 0.001) and Braak stage (p = 0.003). Similarly, 
the proportion of APOE ε4 carriers in the high-severity pathology group (CERAD 44%; 
Braak 46%) was significantly greater than that in the low-severity pathology group 
(CERAD 21%; Braak 21%) for both CERAD (p = 0.03) and Braak stage (p = 0.04). 
The age at which the initial MC test was conducted ranged from 53 to 78 years, and 
age at death ranged from 72 to 104 years. The number of years between initial testing 
and death ranged from 12 to 26 years (mean 21.3 ± 3.5 years). 
Assessment of MC Test Scores and Relationship to Pathology
Using scores from the first test, only the MC task was able to differentiate between 
CERAD 0–A and CERAD B–C groups and between Braak stage 0–II and Braak 
stage III–VI groups (Table 2). This was only the case for scores reflecting both correct 
object and correct sector. Scores for objects recalled, regardless of sector assigned, 
were not able to differentiate between pathology groups, indicating that the spatial 
aspect of the MC test was the predictive element.
Two approaches were used to assess the relationship between MC scores and 
pathology: baseline MC scores and predicted MC scores at 65 years. As baseline MC 
scores cover a wide range of ages (range of 25 years; mean 66.3), knowledge of the 
ability of scores to distin-guish between pathology groups at a fixed age would be 
preferable. There were a total of 231 MC test results for the 75 participants (mean 3 
tests per person). In the random-effects regression models, there was no evidence of 
a learning effect (p = 0.45 for learning term). As a result of calculating the standard 
deviation on the corrected value, the age effect was effectively zero (implying that the 
rate of decline did not vary between people), but there was evidence that scores 
changed with age non-linearly (p value for quadratic term in model = 0.02) with a 
much larger annual decline at older ages compared to younger ages. For example, 
the model predicted an annual decline of 0.11 at age 70 years but 0.62 at age 80 
years. Predicted MC scores at age 65 years were obtained from the quadratic model 
with no learning effect.
Strong negative correlations were observed between the CERAD score (0, A, B or 
C) and both baseline (rs = –0.26, p = 0.03) and predicted (rs = –0.34, p = 0.003) MC
scores. Similarly, strong negative correlations were observed between Braak stage (0–
VI) and both baseline  (rs = –0.28, p = 0.02) and predicted (rs = –0.34, p = 0.03) MC
scores. Both baseline MC scores and predicted MC scores at 65 years were able to
Table 1. Descriptive characteristics, stratified by neuropathological outcome, for the subset of 
individuals from The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old 
Age cohort who 
displayed either AD or normal ageing pathologyCERAD score Braak stage Total cohort0–A B–C 0–II III–VIMale 14 (33%) 7 (22%) 14 (30%) 7 (25%) 21 (28%)Female 29 (67%) 25 (78%) 33 (70%) 21 (75%) 54 (72%)CI at deatha 9 (21%) 18 (56%) 11 (23%) 16 (57%) 27 (36%)Age at death, yearsMean ± SD 87.5±5.4 87.7±7.2 87.8±5.5 87.3±7.3 87.6±6.2Range 24 32 24 32 32Education in ISCED yearsMean ± SD 15.5±3.6 14.6±3.5 15.5±3.5 14.5±3.6 15.1±3.5Range 12 9 12 9 12
APOE
No ε4 present 29 (67%) 14 (44%) 30 (64%) 13 (46%) 43 (57%)
ε4 present 9 (21%) 14 (44%) 10 (21%) 13 (46%) 23 (31%)Missing 5 (12%) 4 (12%) 7 (15%) 2 (7%) 9 (12%)Age at first MC test, yearsbMean ±SD 66.0±5.2 66.8±5.4 65.8±5.3 67.2±5.2 66.3±5.3Range 22 22 22 22 25Baseline MC scorebMean ± SD 9±2 7±2 8±2 7±2 8±2Range 8 8 8 6 8Predicted MC score at age 65Mean ± SD 8±1 7±2 8±1 7±1 8±1Range 5 5 5 5 5
AD, Alzheimer disease; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CI, 
cognitive impairment; SD, standard deviation; MC, Memory Circle. a Two of the subset of 75 
individuals did not have clinical information available, and, therefore, no assumption of cognitive 
impairment could be made. b Three of the subset of 75 individuals did not participate in test battery B; 
therefore, mean age at testing and baseline MC score for this variable is for 72 cohort individuals.
differentiate between individuals who were in CERAD 0–A group and those in CERAD 
B–C group, as well as between those in Braak 0–II group and those in Braak III–VI 
group (Table 3). Specifically, the odds of reaching Braak stage III–VI significantly 
increased for every unit decrease in baseline MC score (OR = 0.79, 95% CI 0.63–0.99), 
and similarly for CERAD stage B or C (OR = 0.78, 95% CI 0.63–0.98).
After adjustment for APOE, sex and level of education, the ORs for baseline MC 
scores were unchanged, although significance values decreased slightly as these 
analyses only included 64 individuals due to missing MC score/APOE data. 
Similarly, for predicted MC scores at 65 years, the OR for CERAD (OR = 0.66, 95% CI 
0.42–1.02) and that for Braak stage (OR = 0.54, CI 0.33–0.87) were essentially 
unchanged – although the MC score for CERAD was no longer significant (p = 0.06) due 
to reduced sample size (Table 4).
Table 2. Median initial test scores (range) for all tests undertaken in The University of Manchester 
Longitu-dinal Study of Cognition in Normal Healthy Old AgeCognitive test CERAD score p value Braak stage p value0–A B–C 0–II III–VIAH4 test 1 41 (37) 36 (35) 0.10 40 (37) 35 (35) 0.06AH4 test 2 36 (33) 35.5 (40) 0.93 36 (41) 35 (32) 0.33Mill Hill A 25 (16) 26 (16) 0.59 25 (16) 25.5 (16) 0.79Mill Hill B 20 (21) 21 (25) 0.56 20 (23) 20.5 (25) 0.96VFR 30 9 (12) 10 (16) 0.61 9 (12) 10 (16) 0.75PR Memory 33 (22) 32 (14) 0.43 33 (22) 32 (14) 0.44Culture Fair 31 (31) 29.5 (20) 0.41 31.5 (31) 29 (20) 0.19WAIS 81.1 (55.4) 84.5 (50) 0.49 81.1 (55.4) 85.1 (50) 0.72Visual Search 208.5 (146) 204 (155) 0.61 219 (146) 202 (155) 0.43Alphabet Coding 228.5 (192) 222 (167) 0.14 231 (192) 212 (167) 0.06VFR 10 7 (7) 7 (5) 0.98 7 (7) 7 (5) 0.69Shapes and Location 36 (12) 36 (13) 0.39 36 (12) 36 (13) 0.17Propositions/People 7 (10) 6 (7) 0.52 7 (10) 6 (7) 0.36Memory Circle 9 (8) 8 (8) 0.02 9 (8) 8 (6) 0.03
Comparison by Mann-Whitney U test showed that only one cognitive test (Memory Circle) 
could differentiate between pathology groups for CERAD and Braak stage. CERAD, Consortium to 
Establish a Registry for Alzheimer’s Disease; AH, Alice Heim; VFR, Verbal Free Recall; PR, Pictorial 
Recognition; WAIS, Wechsler Adult Intelligence Scale.
Table 3. Odds ratios and AUC values for baseline MC test scores and predicted MC test scores at 65 
years when comparing individuals with CERAD score 0–A and B–C or Braak stage 0–II and III–VIBaseline MC test scores Predicted MC test scores at 65 years
n OR 95% CI pvalue AUC n OR 95% CI pvalue AUCCERAD score 72 0.78 0.63–0.98 0.04 0.66 75 0.60 0.40–0.90 0.01 0.64Braak stage 72 0.79 0.63–0.99 0.04 0.65 75 0.51 0.33–0.80 0.003 0.72
AUC, area under the curve; MC, Memory Circle; CERAD, Consortium to Establish a Registry for 
Alzheimer’s Disease; OR, odds ratio; CI, confidence interval.
The area under the curve (AUC) value for baseline MC scores had a similar value to 
APOE for both CERAD (MC test: AUC = 0.66, 95% CI 0.53–0.79; APOE: AUC = 0.63, 
95% C: 0.49–0.77) and Braak stage (MC test: AUC = 0.65, 95% CI 0.52–0.77; APOE: 
AUC = 0.63, 95% CI 0.48–0.77). Similarly, predicted MC scores at 65 years (AUC = 
0.67, 95% CI 0.55–0.80) had a compa-rable value to APOE (AUC = 0.63, 95% CI 0.49–
0.77) for CERAD. However, when examining Braak stage, predicted MC scores at 65 
years (AUC = 0.72, 95% CI 0.60–0.84) performed better than APOE (AUC = 0.63, 
95% CI 0.48–0.77). The combined baseline MC scores + APOE model performed well 
for both CERAD (AUC = 0.72, 95% CI 0.59–0.85) and Braak stage  (AUC = 0.71, 
95% CI 0.59–0.84). Similarly, the combined predicted MC scores at 65 years + APOE 
model performed well for both CERAD (AUC = 0.72, 95% CI 0.59–0.85) and Braak stage 
(AUC = 0.75, 95% CI 0.62–0.87). The addition of sex and education level to these 
models had a negligible effect (Table 5).
Receiver-operating characteristic curves (ROC) for baseline MC scores and 
predicted MC scores at age 65 years + APOE models are shown in Figure 2. For 
CERAD and Braak stage, the optimal sensitivity for the predicted MC scores at 65 
years + APOE model was 75 and 81%, respectively, and optimal specificity was 66 and 
53%, respectively. 
Table 4. OR and AUC values for the model incorporating all variables; sex, education level, presence of APOE ε4 alleles 
and baseline MC test scores/predicted MC test scores at 65 years when comparing individuals with CERAD score 0–A 
and B–C or Braak stage 0–II and III–VI
Baseline MC test scores Predicted MC test scores at 65 yearsCERAD (AUC = 0.73; n obs. = 64) Braak stage (AUC = 0.72; n obs. = 64) CERAD (AUC = 0.73; n obs. = 66) Braak stage (AUC = 0.75; n obs. = 66)OR 95% CI pvalue OR 95% CI pvalue OR 95% CI pvalue OR 95% CI pvalueSex 1.32 0.37–4.66 0.67 1.08 0.30–3.85 0.90 1.53 0.45–5.22 0.50 1.19 0.33–4.25 0.79Education 0.97 0.82–1.14 0.71 0.97 0.82–1.14 0.71 0.99 0.84–1.16 0.90 1.02 0.86–1.20 0.85
APOE 4.09 1.28–13.05 0.02 3.88 1.22–12.38 0.02 3.08 1.01–9.42 0.05 2.90 0.92–9.15 0.07MC test 0.78 0.60–1.02 0.07 0.79 0.60–1.03 0.08 0.66 0.42–1.02 0.06 0.54 0.33–0.87 0.01
OR, odds ratio; AUC, area under the curve; MC, Memory Circle; CERAD, Consortium to Establish a Registry for 
Alzheimer’s Disease; obs., observed; CI, confidence interval.
Table 5. Overview of AUC values for all models examined using baseline MC test scores/predicted scores at 65 
years and comparing individuals with CERAD score 0–A and B–C or Braak stage 0–II and III–VIModel Baseline MC test scores Predicted MC scores at 65 years
n AUC value (95% CI) n AUC values (95% CI)CERAD Braak stage CERAD Braak stageMC only 72 0.66 (0.53–0.79) 0.65 (0.52–0.77) 75 0.67 (0.55–0.80) 0.72 (0.60–0.84)
APOE only 66 0.63 (0.49–0.77) 0.63 (0.48–0.77) 66 0.63 (0.49–0.77) 0.63 (0.48–0.77)MC + APOE 64 0.72 (0.59–0.85) 0.71 (0.59–0.84) 66 0.72 (0.59–0.85) 0.75 (0.62–0.87)MC + sex + APOE + education 64 0.73 (0.60–0.85) 0.72 (0.60–0.85) 66 0.73 (0.60–0.85) 0.75 (0.63–0.88)
The inclusion of APOE with baseline MC score/predicted scores at 65 years increases the area under curve. However, the 
addition of sex and education shows a negligible effect. AUC, area under the curve; MC, Memory Circle; CERAD, 
Consortium to Establish a Registry for Alzheimer’s Disease; CI, confidence interval.
Discussion
This study examines relationships between MC scores, obtained between 12 and 26 
years before death (mean 21.3 ± 3.5 years), and the extent of AD-type pathology 
present at post mortem. Stratification based on Alzheimer-type pathology avoided 
potential effects of confounders with pathologies other than those associated with AD. 
We found an association of both baseline MC score and predicted MC score at 65 years 
with the eventual extent of AD pathology post mortem. Sex, age at testing (for either test 
battery), age at death and ISCED years of education did not influence pathology. This 
suggests that the MC test could contribute to a screening exercise to identify individuals 
at risk of developing sufficient AD-type pathology in future years which would impose 
clinically apparent dementia.
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Fig. 2. ROC curves for the baseline MC score + APOE (a, b) and predicted MC score at age 65 years + 
APOE (c, d) models. The AUC for a (AUC = 0.72, 95% CI 0.59–0.85) and c (AUC = 0.72, 95% CI 
0.59–0.85) shows the level of discrimination between CERAD 0–A and CERAD B–C. The AUC for b 
(AUC = 0.71, 95% CI 0.59–0.84) and d (AUC = 0.75, 95% CI 0.62–0.87) shows the level of 
discrimination between Braak stage 0–II and III–VI. ROC, receiver-operating characteristic; MC, 
Memory Circle test; AUC, area under the ROC curve; CI, confi-dence interval.
Previous studies have shown that combinations of cognitive tests are able to 
predict Braak stage [18]. Furthermore, scores on tests of episodic memory [16] and 
recognition memory [17] can predict Braak stage independently from other risk 
factors of dementia. Where previous studies have highlighted the capabilities of a 
test to distinguish between Braak stages approximately 1–5 years before death, our 
study greatly extends the length of time between testing and death and shows the 
possibility of estimating the broad Braak stage of an individual decades before death. 
That scores from the MC task also associate with the CERAD score has not been 
previously reported. However, as CERAD scoring criteria are based on densities of 
neuritic plaques, which contain degenerating neuronal processes along with tau-paired 
helical filaments, such a finding is unsurprising.
The MC test assesses visuospatial episodic memory, presumably tapping into 
neural pathways linking temporal lobe and hippocampus (traditionally associated with 
memory function) with posterior parietal lobe (which governs spatial awareness). It is 
instructive that memory for where objects are located proved a better predictor of later 
AD pathology than memory for what those objects are. This is consistent with reports of 
topographical memory impairments in MCI and early AD and network-level 
degeneration incorporating posterior cortical as well as medial temporal structures 
[19]. Our findings imply that the MC test is indexing changes in connectivity within that 
network many years earlier than what has been previously recorded.
There are several potential limitations to the study. Brain donation was not initially 
part of the original study, only being introduced in 2004. This meant that many 
potential dona-tions were lost. Common to all autopsy-based studies, sample size is a 
limitation. Although brain donation was offered to all surviving participants in 2004, only 
312 individuals agreed to donation. The geographical areas covered by the study (Greater 
Manchester and Newcastle) could potentially influence outcomes: individuals in large, 
industrial, northern cities might not reflect society as a whole. As with many 
observational studies, our cohort is self-selected and may not necessarily be 
representative of the general population. However, whilst it is possible that test scores 
of participants in the present study may be higher or lower than the population average, 
there does not seem to be any evidence that a different relationship would be found 
in the general population. 
Although modest, our findings indicate that a simple test of cognitive function can 
distin-guish those individuals who are destined to develop sufficient AD-type pathology 
over subse-quent decades to culminate in clinical dementia from those who would 
develop only limited changes and remain cognitively unimpaired. Such “at-risk” 
individuals could be targeted for interventions, including lifestyle adjustments towards 
cognitively stimulating environments, physical activity, healthy diets [28, 29] or perhaps 
utilising anti-Aβ therapies [30], long before their level of cognitive change brings them to 
the attention of medical practice, with a potential influence on the trajectory of their 
disease. 
Importantly, the MC test is cheap, well tolerated and easy to implement, even over 
the periods of multiple testing needed for the evaluation of drug efficacy, and it can be 
performed quickly and safely, even at home. This sets it apart from more invasive tests, 
such as blood/cerebrospinal fluid sampling and brain imaging, which need to be 
performed in a clinical setting and can be expensive to conduct and evaluate over the 
extensive periods required in clinical trials. Our findings may facilitate treatments for 
AD by identifying people “at risk” decades before clinical signs might be anticipated 
and in whom the prospects of preventing disease might be realistic.
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